GenBio AI
Category: AI in Biotech / Drug Discovery
Palo Alto-based AI company building AIDO (AI-Driven Digital Organism), a system of multiscale foundation models that simulate human cells from DNA/RNA through protein behavior to whole-cell level, co-founded by 2024 Nobel laureate David Baker. GenBio AI was founded in 2024. The company is led by Fred Hu, PhD. Based in Palo Alto, California, USA. Team size: 101-500. Latest round: Undisclosed. Key investors include Primavera Capital (Fred Hu), Mohamed Bin Zayed University of AI (MBZUAI).
- Founded
- 2024
- Headquarters
- Palo Alto, California, USA
- Team size
- 101-500
Value proposition
Building the world model for human biology — a programmable virtual cell that simulates how a human cell reacts to gene knockouts, drugs, and other perturbations, enabling in silico experimentation to accelerate drug discovery and reduce wet-lab and animal testing.
Products and solutions
AIDO (AI-Driven Digital Organism) — a system of multiscale foundation models (AIDO.DNA, AIDO.RNA, AIDO.Protein, AIDO.Cell), AIDO Cell — a general-purpose whole-cell simulator (world model) supporting K562 and HepG2 human cell lines, AIDO.Builder — agentic AI system for autonomous model construction, open-source models on HuggingFace and GitHub (GB.ModelGenerator).
Unique value
First system capable of simulating a human cell end-to-end (DNA → RNA → protein → whole-cell) and predicting perturbation responses, backed by a Nobel laureate co-founder and a global scientific team from Stanford, Carnegie Mellon, Harvard, and MBZUAI.
Target customer
Pharmaceutical and biotech companies, drug discovery researchers, and biomedical research institutions seeking AI-driven in silico experimentation.
Industries served
Drug discovery, biotechnology, personalized medicine, bioengineering, biomedical research, synthetic biology
Technology advantage
Multiscale foundation-model architecture spanning molecular to cellular scales; agentic AI (AIDO.Builder) for autonomous model construction; integration with NVIDIA BioNeMo ecosystem and Google Cloud; open-source model releases on HuggingFace/GitHub.
How they differentiate
Unlike AlphaFold (single-protein structure prediction), AIDO Cell simulates the entire cell as a continuous molecular-to-cellular system; emphasizes whole-cell world modeling with agentic autonomous model-building, backed by a Nobel laureate co-founder and global academic network.
Main competitors
Chai Discovery, Xaira Therapeutics, EvolutionaryScale, Biohub (Chan Zuckerberg Initiative AI Virtual Cell)
Key partnerships
NVIDIA (BioNeMo, Megatron, NIM microservices, BioNeMo Agent Toolkit), Google Cloud (powering six specialized AI models), satellite labs in Paris and Abu Dhabi, founders affiliated with Stanford, Carnegie Mellon, Harvard, Mohamed Bin Zayed University of AI, Weizmann Institute.
Major milestones
Founded 2024, released AIDO.Cell-100M (v1.0) end of 2024, launched AIDO Cell whole-cell simulator (Aug 18, 2026), published framework in Nature Medicine, announced NVIDIA BioNeMo partnership, expanded global leadership with Ziv Bar-Joseph (Feb 2025) and Emma Lundberg (Jun 2025).
Growth metrics
~66 employees (Tracxn as of Jun 2026); LinkedIn self-reports 51-200 with ~68 profiles listed
Market positioning
Early-stage leader in the emerging AI virtual-cell / digital-organism space, competing with well-funded rivals (Xaira, Chai Discovery) in the race to build predictive whole-cell models for drug discovery.
Geographic focus
Global — HQ in Palo Alto (US) with satellite labs in Paris (France) and Abu Dhabi (UAE); competes against US and China-based virtual-cell startups.
About Fred Hu, PhD
Founder, Chairman & CEO of Primavera Capital Group (2011-present); ex-Goldman Sachs rainmaker; Harvard University. Global investment leader bringing AI and biology together.
Latest news about GenBio AI
More AI in Biotech / Drug Discovery companies
Official website: https://genbio.ai/